Freeman S L, O'Brien P C, Rizza R A
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905.
Diabetes Res Clin Pract. 1991 Jul;12(3):187-92. doi: 10.1016/0168-8227(91)90076-p.
To determine the suitability of a single subcutaneous evening injection of human ultralente (UL) as the basal component of an intensive insulin therapy program, insulin concentrations were measured in five insulin-dependent diabetic volunteers over a 40-h period. Each patient had been maintained on a human UL-based program for at least one month prior to the study. All short-acting insulin was withheld during the study. The onset of action of human UL was 2 to 4 h, and a broad, variable peak was observed between 6 and 12 h after each injection. We concluded that human UL does not provide constant basal insulin concentrations. When human UL is considered as part of an intensive insulin therapy program, this potential disadvantage must be weighed against the potential advantage of low antigenicity.
为了确定单次皮下注射人超长效胰岛素（UL）作为强化胰岛素治疗方案基础成分的适用性，在5名胰岛素依赖型糖尿病志愿者身上进行了为期40小时的胰岛素浓度测定。在研究前，每位患者均已接受基于人UL的治疗方案至少一个月。研究期间停用所有短效胰岛素。人UL的起效时间为2至4小时，每次注射后6至12小时观察到一个宽泛且可变的峰值。我们得出结论，人UL不能提供恒定的基础胰岛素浓度。当将人UL视为强化胰岛素治疗方案的一部分时，必须权衡这种潜在的劣势与低抗原性的潜在优势。
